{"id":480227,"date":"2020-04-20T11:34:02","date_gmt":"2020-04-20T11:34:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=480227"},"modified":"2020-04-20T11:34:02","modified_gmt":"2020-04-20T11:34:02","slug":"postherpetic-neuralgia-companies-involved-and-emerging-therapies","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/postherpetic-neuralgia-companies-involved-and-emerging-therapies_480227.html","title":{"rendered":"Postherpetic Neuralgia: Companies Involved and Emerging Therapies"},"content":{"rendered":"
\"Postherpetic<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
“Postherpetic Neuralgia Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Postherpetic Neuralgia market. A detailed picture of the Postherpetic Neuralgia pipeline landscape is provided, which includes the disease overview and Postherpetic Neuralgia treatment guidelines.\n<\/div>\n

“Postherpetic Neuralgia Pipeline Insight, 2020<\/a>” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the <\/span>Postherpetic Neuralgia <\/span>market. A detailed picture of the <\/span>Postherpetic Neuralgia <\/span>pipeline landscape is provided, which includes the disease overview and <\/span>Postherpetic Neuralgia <\/span>treatment guidelines. <\/span><\/p>\n

The assessment part of the report embraces in-depth <\/span>Postherpetic Neuralgia <\/span>commercial assessment and clinical assessment of the <\/span>Postherpetic Neuralgia <\/span>pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, <\/span>Postherpetic Neuralgia <\/span>collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.<\/span><\/p>\n

\"\"<\/strong><\/p>\n

Request for sample pages: https:\/\/www.delveinsight.com\/sample-request\/postherpetic-neuralgia-pipeline-insight<\/strong><\/p>\n

The launch of the emerging therapies is expected to significantly impact Postherpetic Neuralgia treatment scenario in the upcoming years:-<\/strong>
Drugs covered<\/strong>
1. LAT8881<\/span>
2. EMA401<\/span>
3. TV-45070<\/span>
And many others<\/span><\/p>\n

The key players in Postherpetic Neuralgia market are:<\/strong>
1. Lateral Pharma<\/span>
2. Novartis Pharmaceuticals<\/span>
3. Teva Pharmaceutical<\/span>
And many others<\/span><\/p>\n

Table of contents:<\/strong>
1. Report Introduction<\/span><\/p>\n

2. Executive Summary<\/span><\/p>\n

3. SWOT Analysis<\/span><\/p>\n

4. Postherpetic Neuralgia Market Overview at a Glance<\/span><\/p>\n

5. Postherpetic Neuralgia Disease Background and Overview<\/span><\/p>\n

6. Postherpetic Neuralgia Epidemiology and Patient Population<\/span><\/p>\n

7. Postherpetic Neuralgia Country-Wise Epidemiology<\/span><\/p>\n

7.1. United States<\/span><\/p>\n

7.2. EU-5<\/span><\/p>\n

7.2.1. Germany<\/span><\/p>\n

7.2.2. France<\/span><\/p>\n

7.2.3. Italy<\/span><\/p>\n

7.2.4. Spain<\/span><\/p>\n

7.2.5. United Kingdom<\/span><\/p>\n

7.3. Japan<\/span><\/p>\n

7. Postherpetic Neuralgia Treatment & Medical Practices<\/span><\/p>\n

8. Postherpetic Neuralgia Marketed Drug<\/span><\/p>\n

8.1. HORIZANT: GlaxoSmithKline<\/span><\/p>\n

9. Postherpetic Neuralgia Emerging Therapies<\/span><\/p>\n

9.1. Key Cross Competition<\/span><\/p>\n

9.2. LAT8881: Lateral Pharma<\/span><\/p>\n

9.3. EMA401: Novartis Pharmaceuticals<\/span><\/p>\n

9.4. TV-45070: Teva Pharmaceutical<\/span><\/p>\n

12. Attribute Analysis<\/span><\/p>\n

13. Postherpetic Neuralgia Market Size<\/span><\/p>\n

14. 7MM Postherpetic Neuralgia : Country-Wise Market Analysis<\/span><\/p>\n

14.1. United States<\/span><\/p>\n

14.2. Germany<\/span><\/p>\n

14.3. France<\/span><\/p>\n

14.4. Italy<\/span><\/p>\n

14.5. Spain<\/span><\/p>\n

14.6. United Kingdom<\/span><\/p>\n

14.7. Japan<\/span><\/p>\n

15. Market Access and Reimbursement<\/span><\/p>\n

16. Market Drivers<\/span><\/p>\n

17. Market Barriers<\/span><\/p>\n

18. Appendix<\/span><\/p>\n

19. Postherpetic Neuralgia Report Methodology<\/span><\/p>\n

20. DelveInsight Capabilities<\/span><\/p>\n

21. Disclaimer<\/span><\/p>\n

22. About DelveInsight<\/span><\/p>\n

About DelveInsight:<\/strong>
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.<\/span><\/span><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Kritika Rehani
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 9193216187
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Las Vegas
State:<\/strong> Nevada
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

DelveInsight Business Research LLP “Postherpetic Neuralgia Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Postherpetic Neuralgia market. A detailed picture of the Postherpetic Neuralgia pipeline landscape is provided, which … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-480227","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/480227","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=480227"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/480227\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=480227"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=480227"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=480227"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}